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Recently,  Takahashi  and  Yamanaka 
(2006)  reported  that  differentiated 
mouse cells can acquire de novo pluri-
potency  upon  the  overexpression  of 
four transcription factors, the so-called 
Yamanaka cocktail (Oct4, Sox2, Klf4, 
and c-Myc); only 1 yr later, the experi-
ment  was  successfully  reproduced  in 
human somatic cells (Takahashi et al., 
2007). This finding offers new oppor-
tunities for regenerative medicine, as in-
duced pluripotent stem cells (iPSCs) may 
represent a rejection-free tissue source, 
and thus could be generated and con-
sidered a patient-specific therapy. In 
addition, iPSCs obtained from diseased 
human tissues offer a new tool to study 
disease modeling and drug screening.
Reprogramming  highlights  the 
ability of somatic cells to revert their 
fate toward a state of pluripotency, a 
de-differentiation  process  resembling 
tumor formation. In this line of think-
ing, several groups (Hong et al., 2009; 
Kawamura et al., 2009; Li et al., 2009; 
Marión  et  al.,  2009;  Utikal  et  al.,   
2009) reported that p53, a tumor sup-
pressor transcription factor, also acts as a 
barrier to somatic cell reprogramming. 
In addition, in this issue Sarig et al. sug-
gest that a mutant form of p53 actually 
increases  the  efficiency  of  the  repro-
gramming process beyond that facili-
tated by the absence of p53 alone.
Role of p53 during induction  
of pluripotency
Although the plasticity of differentiated 
cells has been demonstrated by different 
approaches (Yamanaka and Blau, 2010), 
several mechanisms prevent committed 
cells from de-differentiating into cells 
of an embryonic state, thus preventing 
tumor formation. Surprisingly, germ-
line stem cells (GSCs) derived from neo-
natal, but not adult, testes have been 
described to spontaneously revert to 
multipotent GSCs at a very low effi-
ciency,  which  could  be  increased  by 
depleting p53 (Kanatsu-Shinohara et al., 
2004).  These  results  correlate  with  a 
100-fold increase in the incidence of tes-
ticular teratoma reported in p53 knock-
out mice (Lam and Nadeau, 2003) and 
establish a relationship between pluri-
potency, tumorigenesis, and p53. How-
ever, further studies demonstrated that 
pluripotent stem cells could be derived 
from GSCs obtained from adult testis 
without manipulating the p53 pathway 
(Ko et al., 2009).
As  the  inefficiency  of  the  repro-
gramming process is a major limitation 
to the clinical use of iPSCs, many ef-
forts have been directed at improving 
the  efficiency  of  reprogramming.  An 
initial hypothesis postulated that the 
limiting  step  in  the  reprogramming 
process was achieveming the appropri-
ate, or correct, level of each exogenous 
transcription factor in each cell during 
retroviral infection. To investigate this 
issue, Wernig  et al. (2008) generated 
chimeric mice from iPSCs obtained with 
inducible  lentiviral  vectors  encoding 
Oct4, Sox2, Klf4, and c-Myc. How-
ever, only 1–3% of mouse embryonic 
fibroblasts (MEFs) isolated from these 
mice were able to give rise to secondary 
iPSCs after lentivirus induction, even 
when all the cells contained exactly 
the same number of viral integrations 
(Wernig et al., 2008). These findings 
suggest that other mechanisms, rather 
than  the  right  stoichiometry  among 
transcription factors, were responsible 
for the low rate of reprogramming. 
The suggestion that only a rare popula-
tion of MEFs could be reprogrammed 
was then offered, but was subsequently 
discounted because of the successful 
reprogramming of different cell types 
during different stages of differentiation 
(Yamanaka and Blau, 2010).
Yamanaka  (2007)  suggested  that 
c-Myc  might  induce  p53-dependent 
apoptosis in fibroblasts, which in turn 
would lead to a reduced rate of repro-
gramming. The next year, Zhao et al. 
showed that silencing of p53 combined 
with overexpression of Utf1 produced 
a 100-fold increase in iPSC formation 
(Zhao  et  al.,  2008).  Those  authors 
proposed that inhibition of p53 could 
block apoptosis and senescence, thus 
facilitating reprogramming. Recently, 
these suggestions have been demon-
strated experimentally, and several re-
ports have described the role played   
by p53 during different stages of the 
reprogramming process (Hong et al., 
2009; Kawamura et al., 2009; Li et al.,   
2009;  Marión  et  al.,  2009;  Utikal   
et al., 2009; Sarig et al., 2010). After 
retroviral infection, the overexpression 
of  exogenous  transcription  factors  is 
thought to activate p53, leading to cell 
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fibroblasts at a very low efficiency with 
only OCT4 and SOX2, in the absence 
of KLF4. However, Zhao et al. (2008) 
could not generate iPSCs in the absence 
of KLF4, even after silencing p53. Nev-
ertheless, Melton et al. (Huangfu et al., 
2008) successfully reprogrammed human 
fibroblasts with only OCT4 and SOX2 
in the presence of valproic acid (VPA), 
without inhibiting p53, also at a very 
low efficiency. It would be very inter-
esting to examine whether VPA acts 
either by disturbing the p53 pathway or 
by increasing the proliferation rate or 
whether its effect is simply an outcome 
of chromatin modifications and global 
transcriptional changes.
p53-deficient or mutant iPSCs present 
tumor-like features
Half of all human cancers contain mis-
sense mutations in p53, causing inacti-
vation of the tumor suppressor factor 
(Hollstein et al., 1991). Most of these 
mutations not only inhibit p53 tumor 
suppressor  activity,  but  also  engender 
the mutated protein with an oncogenic 
ability,  referred  as  a  gain  of  function 
(Brosh and Rotter, 2009). The mouse   
p53-R172H  mutation,  R175H  in   
human, causes a global conformational 
distortion of the p53 protein that leads   
to tumor cells with an additional growth 
advantage, thereby producing a very 
aggressive tumor phenotype in vitro 
(Donehower and Lozano, 2009). One 
gain of function described for this p53 
mutant is its ability to interfere with 
miRNA biogenesis, decreasing the avail-
ability of several mature miRNAs in-
volved in the p53 response to DNA 
damage (Suzuki et al., 2009).
Sarig et al. (2010) explored the role of 
the R172H p53 mutant in pluripotency 
induction. To this end, those authors 
derived  MEFs  from  p53  R172H–
knockin mice (Lang et al., 2004) and 
showed that p53 mutant MEFs were 
reprogrammed  more  efficiently  than 
MEFs derived from either wild-type or 
p53 knockout mice. They also showed 
a higher reprogramming efficiency in 
p53 mutant MEFs using only two fac-
tors (Oct4 and Sox2) compared with 
p53 knockout MEFs using three factors 
(Oct4, Sox2, and Klf4), suggesting an 
(2009) only detected background levels 
of apoptosis in the B cells, the effect of 
p53 on reprogramming appears to be 
more pronounced in cell types with high 
tolerance to DNA damage. This find-
ing may account for the different repro-
gramming  rates  reported  for  different 
cell types (Yamanaka and Blau, 2010).   
In contrast, another group compared the 
reprogramming efficiency of wild-type 
and  p53-depleted  MEFs  cultured  in 
0.5  and  15%  fetal  bovine  serum,  re-
spectively.  The  p53  knockout  MEFs 
exhibited higher reprogramming effi-
ciency,  but  lower  proliferation  rate, 
compared with wild-type MEFs, thus 
arguing  against  an  effect  of  p53  on   
the cell cycle as the cause for the in-
creased reprogramming efficiency (Utikal 
et al., 2009).
As Klf4 has been observed to repress 
p53 (Rowland et al., 2005), it follows that 
Klf4 is dispensable for reprogramming 
in p53-depleted MEFs. Consistent with 
this assumption, Kawamura et al. (2009) 
reported that iPSCs could be generated 
from  p53-depleted  human  embryonic 
cycle arrest and apoptosis. In addition, 
at the time of pluripotency induction, a 
second round of p53-dependent apop-
tosis is assumed to take place, with cells 
presenting with DNA damage and/or 
chromosomal  abnormalities  excluded 
from  becoming  iPSCs.  Thus,  it  is 
thought  that  inhibiting  p53  prevents 
apoptosis, senescence, and cell cycle ar-
rest, thereby increasing the efficiency of 
reprogramming (Fig. 1).
However, Hanna et al. (2009) re-
ported that most cells were capable of 
becoming iPSCs without depleting p53 
or immortalizing the cells. For this pur-
pose, those authors used a homogeneous 
population  of  clonal  B  cells  obtained 
from secondary iPSC-generated mice. 
After  induction,  the  majority  of  cells 
were reprogrammed. In the absence of 
p53, the process was accelerated, corre-
lating with an increase in the prolifera-
tion rate. Thus, in this model, lack of p53 
only increased the kinetics of repro-
gramming, without affecting the overall 
efficiency of the reprogramming pro-
cess (Hanna et al., 2009). As Hanna et al. 
Figure 1.  The p53 pathway decreases the efficiency of reprogramming to iPSCs. In the pres-
ence of p53, senescent cells or cells with DNA damage undergo apoptosis, thereby preventing the 
generation of iPSCs. When the p53 pathway is silenced or mutated, these suboptimal cells can  
become iPSCs, thus increasing the efficiency of reprogramming. In addition, in the absence of  
p53-dependent cell cycle arrest, the reprogramming process is accelerated. After transplantation of 
wild-type iPSCs into immunodeficient mice, these cells give rise to teratomas characterized by  
differentiated tissues of all three germ layers. In contrast, teratomas generated from p53-deficient 
iPSCs also contain undifferentiated tissues, thus resembling tumor growths.JEM VOL. 207, September 27, 2010 2047
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In summary, future efforts to increase 
the efficiency of somatic cell reprogram-
ming should preferably be aimed at se-
lecting for primary cells with lower levels 
of p53 and/or higher proliferative ability, 
rather than silencing the p53 pathway.
We thank Dong Wook Han for critical comments on 
the manuscript.
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